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What is already known about this subject? 
- Maternal diet during pregnancy may contribute to the risk of offspring adiposity 
- Maternal intake of n-6 polyunsaturated fatty acids (PUFAs) during pregnancy has been 
proposed to contribute to higher offspring adiposity, while intake of n-3 polyunsaturated 
fatty acids has been suggested to contribute to less adiposity 
- Limited data from human studies show mixed results and no clear association between 
maternal fatty acid intake and offspring adiposity 
What this study adds? 
- This study adds to the small pool of human studies exploring maternal fatty acid intake 
during pregnancy and offspring overweight and obesity 
- We provide data on maternal intake of several individual fatty acids 
- Both low and high maternal intake ratios of n-6:n-3 PUFAs in late pregnancy were 
associated with an increased risk of later obesity in girls, while a higher intake ratio of 
arachidonic acid (20:4n-6): docosahexaenoic acid + eicosapentaenoic acid was associated 
with a decreased risk of obesity in boys. 
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Abstract  
Background: Maternal diet during pregnancy may contribute to the risk of offspring adiposity. 
Objectives: To explore the associations between maternal antenatal dietary fatty acid intake and the 
risk of offspring overweight and obesity at the ages of 2 to 7 years. 
Methods: In a prospective Finnish birth cohort with 3807 mother-child pairs, maternal diet in late 
pregnancy was assessed with a food frequency questionnaire. Intakes of total fatty acids and 
individual saturated (SFAs), monounsaturated (MUFAs), and polyunsaturated fatty acids (PUFAs) 
were calculated. Generalized estimating equation (GEE) models were used to study the associations 
of maternal dietary variables with repeatedly measured offspring overweight and obesity.  
Results: In girls, maternal intake ratio of n-6:n-3 PUFAs had a U-shaped association with obesity 
(adjusted OR for the lowest 2.0 [95% CI 1.27-3.20] and the highest 1.7 [1.03-2.73] vs. the two 
middle quartiles of n-6:n-3 PUFAs, p=0.01). In boys, arachidonic acid (20:4n-6): docosahexaenoic 
acid + eicosapentaenoic acid ratio was associated with obesity (adjusted OR for the lowest 1.0 
[0.60-1.57] and the highest 0.5 [0.26-0.88] vs. the two middle quartiles, p=0.02). SFAs and MUFAs 
were not associated with overweight or obesity in either sex. 
Conclusions: Maternal intakes of PUFAs in late pregnancy were associated with risk of later obesity 
differently in girls and boys. 
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Abbreviations 
PUFA Polyunsaturated fatty acid 
DHA Docosahexaenoic acid  
EPA Eicosapentaenoic acid  
DIPP study Type 1 Diabetes Prediction and Prevention study 
FFQ Food frequency questionnaire 
BMI Body mass index 
IOTF International Obesity Task Force 
WHO World Health Organization 
GEE Generalized estimating equations  
SFA Saturated fatty acid  
MUFA Monounsaturated fatty acid 
 
Introduction 
Intrauterine exposures may contribute to the risk of adiposity later in life by affecting 
developmental programming (1). Suggested exposures associated with offspring adiposity include 
maternal nutritional, hormonal, and inflammatory milieus during pregnancy (2-4). Dietary fatty 
acids and their metabolites work as signaling molecules that may modulate gene expression and 
protein function on pathways related to energy balance, endocrine responses, and inflammation (5). 
During pregnancy, maternal fat intake contributes to the fetal fatty acid environment, and may thus 
contribute to child adiposity (5). It has been suggested that a high intake ratio of n-6:n-3 
polyunsaturated fatty acids (PUFAs) exaggerates fetal adipose tissue development because n-6 and 
n-3 PUFAs are competitive substrates with partly different adipogenic and inflammatory effects (6). 
A few cohort studies have investigated maternal dietary intake or plasma concentrations of fatty 
acids during pregnancy in relation to offspring adiposity (7-12). In the only study exploring the 
intake of specific fatty acids, a higher intake of mid-pregnancy n-3 long-chain PUFAs 
(docosahexaenoic acid (DHA) + eicosapentaenoic acid (EPA)) was associated with a lower risk of 
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adiposity in 3-year-olds, whereas a higher ratio of n-6:n-3 was associated with a higher risk (7). Due 
to the limited number of studies and mixed results, the role of maternal PUFAs on offspring 
adiposity remains unclear (5).  
Our aim was to study the associations between maternal late-pregnancy intake of dietary fatty acids, 
including several individual fatty acids, and the longitudinal development of offspring overweight 
and obesity between the ages of 2 and 7 years. 
Methods 
Study population  
The study is part of the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, a large 
population-based birth cohort study of children with HLA-DQBI-conferred susceptibility to type 1 
diabetes (13). At the time of the screening, 99% of the Finnish population was Caucasian, and 
children with two non-Caucasian parents, severe diseases, or anomalies were excluded (13). The 
children participated in follow-up visits, including blood sampling and anthropometric 
measurements, scheduled for 3, 6, 12, 18, and 24 months of age, and annually thereafter, until the 
age of 15 or the onset of type 1 diabetes. Of the 54350 screened children, 7782 infants born in 
Tampere and Oulu University Hospitals between September 1996 and September 2004 were 
invited, and finally 6083 were enrolled into the DIPP Nutrition Study (Supplemental Figure S1). 
Inclusion criteria for the present report were being a singleton and having data for the maternal food 
frequency questionnaire (FFQ), birth size, and at least one weight and height measurement between 
2 and 7 years (± 3 months) of age (Figure S1). Parents gave their written informed consent for 
genetic testing of the newborn and for participation in the follow-up. The study adheres to the 
Declaration of Helsinki, and the local ethics committees approved the study protocol. 
Maternal nutrition  
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The mothers completed a validated 181-item semi-quantitative FFQ concerning their habitual diet 
during the eighth month of pregnancy, the last month preceding the maternity leave in Finland (14). 
The questionnaires were mailed to the mothers after delivery and checked at the 3-month visit. The 
FFQ contained questions on the frequency and amount of foods consumed; fat used in cooking, 
baking, and salad dressing; the extent of home baking; and the use of dietary supplements. These 
questions were used to calculate individual nutrient intakes based on the Finnish Food Composition 
Database (Fineli), and the data were analyzed with the in-house software (Finessi) of the National 
Institute for Health and Welfare, Finland. Energy from dietary fiber was included in the energy 
from carbohydrates and in the total energy. FFQs with >10 missing items were excluded. The 
validity and reproducibility of the FFQ data collection after pregnancy to record diet during eight 
month of pregnancy is generally good (14). 
 
Offspring anthropometrics 
At each visit of a child aged 2 years or older, the body weight was measured using an electronic 
scale in underwear or light indoor clothing, and the height was measured using a wall-mounted 
measure with the child barefoot. Body mass index (BMI, kg/m2) was calculated, and overweight 
(including obesity) and obesity were defined according to the International Obesity Task Force 
(IOTF) (15) and World Health Organization (WHO) criteria (16).  
Covariates 
Information on the maternal level of education, as well as height, weight, and gestational weeks at 
the first and last antenatal visits as recorded in the maternity record book was collected using 
structured questionnaires completed after delivery. Maternal adherence to a glucose intolerance diet 
was based on the question about the mother’s special diet during pregnancy due to disturbances in 
glucose metabolism (answer: yes/no). Maternal BMI was calculated from the weight at the first 
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antenatal visit. The means (standard deviations) of gestational age at the first and the last antenatal 
visits were 9.6 (2.2) and 38.9 (2.0) weeks, respectively. If the first weight measurement was after 
10.0 weeks of gestation, the weight at 10.0 weeks was estimated based on the weight difference 
between the first and last antenatal visit, assuming linear weight gain during the second and third 
trimesters of pregnancy (17). Gestational weight gain rate was calculated by dividing the change in 
weight between the first and the last antenatal visits by the time between measurements in weeks. 
The duration of any breastfeeding was assessed by a dietary questionnaire up to 2 years. 
Information on the number of previous deliveries, gestational age, number of fetuses, offspring sex, 
birth weight and length, maternal age, and smoking during pregnancy was obtained from the birth 
registers of the hospitals. 
Statistical methods 
Differences in baseline characteristics between boys and girls, as well as between included and 
excluded participants, were tested using the Chi Square and Mann–Whitney U tests. IOTF-defined 
overweight (including obesity) and obesity were used as binary outcomes (15). We used generalized 
estimating equation (GEE) models to study the associations of covariates and maternal dietary 
variables on the repeatedly measured offspring overweight and obesity. An autoregressive working 
correlation structure was used to model the correlation of the repeated outcomes. Fatty acid 
variables and fatty acid ratios were energy-adjusted using Willett’s residual method (18) after 
logarithmic transformation. Dietary variables were analyzed as continuous variables and as 
categorized into quartiles; the two middle quartiles were combined and used as the reference 
category. The main analyses (using quartile categorization of the exposure variables) were 
performed separately for boys and girls, and adjusted for maternal BMI, gestational weight gain 
rate, time of the first weight measurement (≤10.0 vs. >10 weeks of pregnancy), glucose intolerance 
diet, education, and smoking during pregnancy, as well as duration of breastfeeding. To test 
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whether offspring sex modified the associations between dietary variables and overweight or 
obesity, we added interaction terms into the models.  
We repeated the adjusted main analysis as follows: 1) excluding children who had developed type 1 
diabetes (n=114) or advanced preclinical diabetes (repeated positivity for at least two predefined 
islet autoantibodies (13) (n=128)) by May or September 2014, respectively; 2) using tertile-based 
exposures; 3) using WHO-defined outcomes and quartile-based exposures. SAS software version 
9.3 (SAS Institute, Cary, NC, USA) was used, and statistical significance was set at p<0.05. 
Results 
Characteristics of the study population 
Altogether 3807 mother-child pairs were included in the analyses (Figure S1). The mothers of 
singletons who were invited to the study but had insufficient data on maternal diet or child growth 
(n=3602), were younger, more likely to be smokers, and had a higher number of previous deliveries 
and a lower level education than those included (19).  
The median follow-up time regarding growth was 7 years (interquartile range (IQR): 6-7) and the 
median number of growth measurements at the age of 2-7 years was 3 (IQR: 2-5) per child. A much 
higher proportion of children was defined as overweight or obese by the WHO than the IOTF 
criteria (Figure 1). 
In general, higher maternal early pregnancy BMI, gestational weight gain rate, and offspring birth 
weight, maternal smoking during pregnancy, a lower level of maternal education, and a shorter 
duration of breastfeeding were associated with an increased odds of offspring overweight or obesity 
(Table 1). There were no differences between mothers of boys and girls in mean intakes of energy, 
the contribution of carbohydrates, proteins, and fats to the total energy intake, or the intakes of fatty 
acids (Table S1, sex-specific data not shown).  
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Maternal dietary intake and offspring overweight 
In girls, none of the categorized maternal dietary factors were associated with overweight in the 
adjusted analysis (Table 2). In boys, higher maternal intake of n-6 PUFA was associated with lower 
adjusted odds of overweight, with borderline significance (Table 2). The unadjusted results are 
shown in Supplemental Table S2. None of the continuous maternal dietary variables were 
associated with overweight in boys or girls.  
Maternal dietary intake and offspring obesity 
In girls, the lowest and highest quartiles of maternal n-3 PUFA intake, n-6:n-3 intake ratio, and 
linoleic acid (18:2n-6):α-linolenic acid (18:3n-3) intake ratio were all associated with greater 
adjusted odds of obesity, compared to the two middle quartiles (Table 2). In boys, maternal intake 
of EPA and intake ratio of arachidonic acid (20:4n-6):DHA+EPA were associated with obesity, 
such that the lowest quartile of EPA intake and the highest quartile of arachidonic acid (20:4n-
6):DHA+EPA intake ratio were associated with lower adjusted odds of obesity (Table 2). The 
unadjusted results are shown in Table S2. None of the continuous maternal dietary variables were 
associated with obesity in boys or girls. 
Interaction and sensitivity analyses 
The sex of the offspring modified the association between n-6:n-3 ratio and obesity, with a 
U-shaped association in girls and no association in boys (for interaction, p=0.04). No other sex 
interactions were observed.  
We excluded children with advanced preclinical or clinical type 1 diabetes. The directions of the 
associations between the dietary variables and overweight or obesity remained similar to those in 
the main analyses. However, the association between EPA intake and obesity in boys was no longer 
statistically significant. 
10 
 
When using tertile-based exposures, the association between maternal n-6:n-3 PUFA intake ratio 
and obesity in girls was slightly stronger, while the associations between n-3 PUFA and linoleic 
acid (18:2n-6):α-linolenic acid (18:3n-3) intake ratio with obesity were weaker (Table S3), 
compared to quartile-based exposures (Table 2). In boys, the results changed only minimally (Table 
S3 vs. Table 2).  
Finally, when using the WHO-defined overweight and obesity, and quartile-based exposures, the 
results were slightly weaker but comparable with the main analyses (Supplemental Table S4 vs. 
Table 2). 
Discussion 
In this prospective birth cohort, maternal intake ratio of n-6:n-3 PUFAs during late pregnancy 
exhibited a U-shaped association with obesity in girls aged 2 to 7 years. In boys, maternal intake 
ratio of arachidonic acid (20:4n-6):DHA+EPA was associated with obesity such that the odds of 
obesity was lower in the highest vs. the two middle quartiles. These associations were consistent 
irrespectively of whether using tertile- or quartile-based exposures, or the IOTF or WHO criteria for 
obesity, and remained significant after adjustment for several putative confounders.  In addition, 
maternal intake of n-3 PUFAs and intake ratio of linoleic acid:α-linolenic acid had a U-shaped 
association with obesity in girls, and lowest intake of maternal EPA intake was associated with 
lower odds of obesity in boys. However, these associations were weaker when using tertile-based 
exposures, or the WHO criteria for obesity. 
To our knowledge, this is the first cohort study reporting associations between maternal antenatal 
intakes of individual fatty acids other than PUFAs and any measure of offspring adiposity. The 
major strengths of the current study are related to the large prospective birth cohort setting and the 
use of a validated FFQ to assess the maternal intake of individual and total fatty acids during late 
pregnancy. Other strengths include the large number of repeated growth measurements and the 
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longitudinal analysis of overweight and obesity. Further, we adjusted the analyses for several 
potential confounders, including duration of breastfeeding. However, we could not adjust for other 
items in offspring nutrition, or physical activity. Although the validity of fat and fatty acid intake by 
FFQ is generally good, it is modest for intakes of oils and low-fat margarines (14). On the other 
hand, a similar FFQ on lactating women correlates well with infant serum concentrations of 
saturated fatty acids (SFAs) and n-3 PUFAs, supporting the suitability of the FFQ for assessing the 
intake of fatty acids (20). 
We mainly used the IOTF BMI cut-offs for child overweight and obesity, which are analogous to 
the widely used adult cut-offs of 25 kg/m2 and 30 kg/m2 (15). Although BMI does not separate fat 
and lean mass, it is accepted as a valid indirect measure of adiposity in children (21) and it strongly 
predicts cardiometabolic risk factors, including overweight, in adulthood (22). The mothers and 
their offspring who were invited to the follow-up but did not have FFQ or growth data differed in 
some aspects from those included in the analysis, which might have caused some selection bias. 
Finally, we cannot rule out chance findings due to multiple testing. However, the main associations 
were also seen in the sensitivity analyses. 
Our findings of an U-shaped association between maternal n-6:n-3 PUFAs intake ratio and obesity 
in girls – and no such association in boys – do not fully support the hypothesis that a higher 
maternal dietary intake ratio of n-6:n-3 PUFAs during pregnancy promotes offspring adiposity (6). 
Our results partly differ from the only previous comparable cohort study (from the US) that found 
an inverse association between maternal intake of n-3 PUFAs during pregnancy and offspring 
obesity (BMI) or skinfold thickness, as well as a direct association between the n-6:n-3 PUFA ratio 
and skinfold thickness (borderline significance for obesity), in both sexes together (7). Our 
observation related to the arachidonic acid:DHA+EPA intake ratio has not been reported before. 
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In Finland, the intake of plant n-3 PUFAs is among the highest in the world due to the high 
consumption of canola oil, and the intake of seafood n-3 PUFAs is above the global mean as well 
(23, 24). Respectively, oils and high-fat margarines were the main sources of the n-3 PUFA intake 
in the current study population (25). On the other hand, intake of n-6 PUFAs in Finland is among 
the lowest, while intake in the US is among the highest, in the world (23). Accordingly, the mean n-
6:n-3 PUFAs ratio was much smaller in the current cohort compared to the US cohort (3.5 vs. 11.1), 
which may explain the partly contrasting observations (7). The potential unbeneficial effects of high 
n-3 PUFA consumption or a low n-6:n-3 PUFA ratio on adiposity may not have been observed 
previously due to much lower plant n-3 PUFA intakes (7). Cohort studies with the n-6:n-3 ratio 
measured in maternal plasma (9-11) or cord blood (26) show inconsistent associations with 
offspring adiposity. The only randomized controlled trial designed to assess the effect of a reduced 
n-6:n-3 intake ratio on offspring adiposity showed no difference between the groups (27).  
We observed no statistically significant association between α-linolenic acid, linoleic acid, 
arachidonic acid, or trans fatty acids and overweight or obesity, which is in line with the findings 
from the US cohort (7). Further, the lack of statistically significant associations between total SFAs, 
monounsaturated fatty acids (MUFAs), and total energy with offspring adiposity is consistent with 
most previous studies (8, 12, 28).  
In addition to the high variation in fatty acid intakes across studies, the inconsistencies in the 
existing results may be due to differences in methods, such as stratification by sex, measures and 
timing of measurement of exposure (fatty acids) and outcome (adiposity), and adjustment for 
potential confounders. We observed different associations between the maternal n-6:n-3 ratio and 
obesity in girls and boys. This may be a true difference, because there are sex differences in fatty 
acid metabolism, although little data is available for prepubertal children (29). Fatty acid exposures 
during different trimesters of pregnancy or during lactation may have different associations with 
offspring adiposity (7). Most previous cohort studies assessed adiposity at only one age point (7, 9), 
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while we used repeated measures. In addition, different outcome measures of adiposity, such as 
BMI, overweight, obesity, or body composition, may result in different associations (7, 10). We 
observed stronger associations when the outcome was obesity compared to overweight, and IOTF-
defined obesity compared to WHO-defined obesity, suggesting that the maternal intake of fatty 
acids might have the most effect on the highest end of the BMI scale. 
Despite the inconsistent directions of associations, in our results and in the literature, PUFAs have 
repeatedly been raised as potential players in adiposity programming. Linoleic acid and α-linolenic 
acid are essential fatty acids and should contribute at least 5% of the total energy intake in pregnant 
women (30). The fetus may synthesize SFAs and MUFAs but has a limited capacity to synthesize 
long-chain-PUFAs, resulting in dependency on maternal PUFA intake and metabolism (5). 
Therefore, the biological rationale supports our results, in which PUFAs in particular seemed to be 
important.  
The generalizability of our results must be considered, because all children in the present study 
carried HLA-conferred susceptibility to type 1 diabetes. Rapid growth may be a risk marker for type 
1 diabetes (31), and therefore the growth pattern might be different in children who later become 
diabetic in comparison to those who remain healthy. However, the exclusion of children with 
advanced preclinical or clinical type 1 diabetes did not change the main results. In addition, the 
prevalence of overweight and obesity in the present study was very similar to that in a population 
sample of Finnish children for girls, and only slightly higher for boys (for example, 13% vs. 11% in 
5-year-olds) (32).  
To conclude, maternal intakes of PUFAs in late pregnancy were associated with risk of later obesity 
differently in girls and boys. We report, for the first time, the lack of associations between maternal 
antenatal intakes of MUFA 18:1 isomers and individual SFAs with offspring overweight and 
obesity.  
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Table and figure legends 
 
Figure 1. Prevalence of overweight and obesity in boys and girls according to the IOTF and WHO 
criteria and mean (standard deviation) BMI from 2 to 7 years, the DIPP Nutrition Study, Finland. 
IOTF = International Obesity Task Force, WHO = World Health Organization, BMI = Body mass 
index, SD = Standard deviation. The number of participants at the ages of 2, 3, 4, 5, 6, and 7 years 
were 1873, 1722, 1562,1470, 1371 and 1240 for boys and 1678, 1567, 1451, 1330, 1230, and 1154 
for girls, respectively. Children aged 2 years ± 3 months were included, but the IOTF criteria start at 
2.0 years. Therefore, the number of participants with the IOTF-defined variables at the age of 2 
years were 1408 for boys and 1243 for girls. The light grey represents overweight without obesity, 
and the total bar represents overweight including obesity.  
 
Table 1. Characteristics of 3807 mothers and their offspring by sex in relation to childhood 
overweight (including obesity), and obesity from the ages of 2 to 7 years according to the IOTF 
criteria, the DIPP Nutrition Study, Finland. 
BMI = body mass index; IQR = interquartile range 
ap-value for difference between girls and boys from the Mann–Whitney U test;  
bOR (95% CI) for overweight (including obesity) and obesity, based on unadjusted generalized 
estimating equation models;  
cAt the time of birth;  
dBased on the first weight measurement during pregnancy: If the first weight measurement was after 
the tenth week of gestation, the weight at the tenth week was estimated based on the weight 
difference between the first and last antenatal visit, assuming a linear weight gain during the second 
and third trimesters of pregnancy; 
eAdjusted with maternal early pregnancy BMI and the time of the first weight measurement (≤10.0 
vs. >10 weeks of pregnancy);  
fp-value for the difference between girls and boys from the Chi-Square test;  
gp-value from type 3 Score test  
The number of individuals with missing data for covariates varied in general between 0 and 100. 
However, data for early pregnancy BMI was missing in 204 mothers and for gestational weight gain 
rate in 226 mothers.  
 
Table 2. Adjusted odds ratios (OR) for offspring overweight (including obesity) and obesity based 
on IOTF criteria from the ages of 2 to 7 years according to quartiles of maternal energy and fatty 
acid intake during pregnancy in 3807 mother-child pairs, the DIPP Nutrition Study, Finland. 
 
The OR (95% CI) are from generalized estimating equations adjusted for maternal early pregnancy 
BMI, gestational weight gain rate, time of the first weight measurement (≤10.0 vs. >10 weeks of 
18 
 
pregnancy), glucose intolerance diet, education, smoking during pregnancy, and duration of 
breastfeeding. p-values are based on type 3 Score test. The fatty acid variables used in the statistical 
analysis were energy-adjusted using Willett’s residual method after logarithmic transformation. The 
sum of the 18:1 isomers consists mainly of oleic acid (18:1 n-9) and cis-vaccenic acid (18:1 n-7). 
IOTF = International Obesity Task Force; E% = percent of daily energy intake; SFA = Saturated 
fatty acid; MUFA = Monounsaturated fatty acid; PUFA = Polyunsaturated fatty acid; DHA = 
Docosahexaenoic acid; EPA = Eicosapentaenoic acid; Q1 =1
st quartile; Q2-3 = the 2 middle quartiles; 
Q4 = 4
th quartile  
 
Table 1. Characteristics of 3807 mothers and their offspring by sex in relation to childhood overweight (including obesity), and obesity from the 
ages of 2 to 7 years according to the IOTF criteria, the DIPP Nutrition Study, Finland. 
 Boys Girls   Boys  Girls 
 (n=1984) (n=1823)   Overweight Obesity  Overweight Obesity 
 Median (IQR) Median (IQR) p-valuea  OR (95% CI) b OR (95% CI) b  OR (95% CI) b OR (95% CI) b 
Maternal age, yearsc  29 (26-33) 29 (26-33) 0.78  1.0 (0.98-1.02) 1.0 (0.96-1.04)  1.0 (0.98-1.02) 1.0 (0.98-1.06) 
Maternal BMI in early pregnancy, 
kg/m2d 
23.5 (21.5-26.3) 23.4 (21.4-26.2) 0.52  1.2 (1.09-1.15) 1.2 (1.11-1.19)  1.2 (1.09-1.13) 1.1 (1.10-1.17) 
Gestational weight gain rate, kg/week 0.43 (0.33-0.52) 0.42 (0.32-0.51) 0.01  4.1 (1.99-8.46) e 9.0 (2.95-27.8) e  2.3 (1.19-4.63) e 4.1 (1.46-11.75) e 
Gestational age, weeks 40.0 (39.0-40.9) 40.1 (39.1-40.9) 0.02  1.0 (0.94-1.08) 1.0 (0.87-1.16)  1.1 (1.00-1.15) 0.9 (0.86-1.05) 
Birth weight, kg  3.7 (3.3-4.0) 3.5 (3.2-3.9) <0.0001  1.8 (1.44-2.33) 1.8 (1.08-3.04)  2.1 (1.70-2.64) 1.6 (1.07-2.33) 
Any breastfeeding, months 7.0 (4.0-11.0) 7.0 (4.0-11.0) 0.26  0.97 (0.95-1.00) 0.95 (0.91-0.99)  0.98 (0.96-1.00) 0.97 (0.93-1.01) 
          
 Number (%) Number (%) p-valuef       
Maternal glucose intolerance diet           
No 1857 (93.6) 1722 (94.5)   1 1  1 1 
Yes 127 (6.4) 101 (5.5) 0.26  1.4 (0.93-2.01) 1.2 (0.60-2.46)  1.4 (0.96-2.02) 0.8 (0.35-1.93) 
Number of previous deliveries          
0  899 (45.4) 836 (46.1)   1 1  1 1 
1  637 (32.2) 574 (31.6)   0.7(0.57-0.96) 0.7 (0.42-1.06)  0.9 (0.71-1.13) 0.9 (0.59-1.40) 
2 276 (14.0) 237 (13.1)   0.8 (0.59-1.19) 0.9 (0.52-1.62)  0.9 (0.64-1.23) 1.3 (0.75-2.14) 
≥3 167 (8.4) 168 (9.3) 0.69  0.9 (0.61-1.32) 0.5 (0.26-1.12)  0.7 (0.46-1.05) 1.0 (0.48-1.93) 
p-valueg     0.15 0.15  0.29 0.75 
Maternal vocational educationc          
None 99 (5.1) 105 (5.9)   1.2 (0.70-2.17) 0.7 (0.23-2.28)  1.7 (1.09-2.75) 2.5 (1.14-5.52) 
Vocational school or course 517 (26.7) 478 (26.8)   1.7 (1.20-2.30) 2.0 (1.10-3.72)  1.4 (1.03-1.85) 2.3 (1.34-3.99) 
Secondary vocational education 868 (44.8) 789 (44.2)   1.3 (0.95-1.73) 1.4 (0.80-2.57)  1.01 (0.77-1.33) 1.2 (0.72-2.15) 
University studies or degree 455 (23.5) 415 (23.2) 0.77  1 1  1 1 
p-valueg     0.02 0.04  0.02 0.007 
Maternal smoking during pregnancy          
No 1761 (91.2) 1614 (90.6)   1 1  1 1 
Yes 169 (8.8) 167 (9.4) 0.51  1.4 (0.94-2.00) 1.7 (0.87-3.30)  1.6 (1.16-2.26) 2.4 (1.46-4.00) 
BMI = body mass index; IQR = interquartile range 
ap-value for difference between girls and boys from the Mann–Whitney U test;  
bOR (95% CI) for overweight (including obesity) and obesity, based on unadjusted generalized estimating equation models;  
cAt the time of birth;  
dBased on the first weight measurement during pregnancy: If the first weight measurement was after the tenth week of gestation, the weight at the 
tenth week was estimated based on the weight difference between the first and last antenatal visit, assuming a linear weight gain during the 
second and third trimesters of pregnancy; 
eAdjusted with maternal early pregnancy BMI and the time of the first weight measurement (≤10.0 vs >10 weeks of pregnancy);  
fp-value for the difference between girls and boys from the Chi-Square test;  
gp-value from type 3 Score test 
The number of individuals with missing data for covariates varied in general between 0 and 100. However, data for early pregnancy BMI was 
missing in 204 mothers and for gestational weight gain rate in 226 mothers.  
 
Table 2. Adjusted odds ratios (OR) for offspring overweight (including obesity) and obesity based 
on IOTF criteria from the ages of 2 to 7 years according to quartiles of maternal energy and fatty 
acid intake during pregnancy in 3807 mother-child pairs, the DIPP Nutrition Study, Finland. 
 Boys (n=1984) Girls (n=1823) 
 Overweight Obesity Overweight Obesity 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Total energy intake, kJ     
Q1 <9300 1.1 (0.79-1.45) 1.2 (0.69-1.97) 1.1 (0.82-1.43) 1.3 (0.82-2.11) 
Q2-3 9300-13400 1 1 1 1 
Q4 > 13400 1.3 (0.97-1.71) 1.5 (0.93-2.57) 0.9 (0.73-1.23) 0.8 (0.50-1.35) 
p-value 0.25 0.32 0.70 0.27 
Carbohydrates, E%     
Q1 <47.2 0.8 (0.62-1.14) 0.9 (0.54-1.64) 1.1 (0.80-1.41) 1.0 (0.63-1.62) 
Q2-3 47.2-53.8 1 1 1 1 
Q4 > 53.8 1.0 (0.75-1.32) 1.0 (0.61-1.65) 1.3 (1.01-1.72) 1.1 (0.70-1.86) 
p-value 0.49 0.97 0.15 0.87 
Proteins, E%     
Q1 <14.7 0.9 (0.64-1.17) 0.8 (0.46-1.35) 1.4 (1.03-1.78) 1.2 (0.72-2.00) 
Q2-3 14.7-17.5 1 1 1 1 
Q4 > 17.5 1.0 (0.72-1.29) 1.1 (0.64-1.79) 1.2 (0.92-1.59) 1.3 (0.83-2.06) 
p-value 0.62 0.56 0.08 0.49 
Fats, E%     
Q1 <30.0 1.0 (0.75-1.30) 0.9 (0.56-1.51) 1.1 (0.85-1.45) 0.8 (0.48-1.27) 
Q2-3 30.0-36.4 1 1 1 1 
Q4 > 36.4 0.8 (0.58-1.06) 1.0 (0.57-1.63) 1.0 (0.75-1.33) 0.9 (0.53-1.40) 
p-value 0.23 0.94 0.74 0.56 
SFA, g     
Q1 1.0 (0.77-1.37) 1.1 (0.64-1.74) 1.2 (0.92-1.56) 0.8 (0.51-1.38) 
Q2-3 1 1 1 1 
Q4  1.0 (0.72-1.30) 1.1 (0.64-1.79) 1.1 (0.81-1.45) 0.9 (0.55-1.48) 
p-value 0.94 0.96 0.43 0.75 
Myristic acid (14:0), g     
Q1 0.9 (0.69-1.23) 0.8 (0.49-1.36) 1.2 (0.92-1.55) 1.1 (0.67-1.74) 
Q2-3 1 1 1 1 
Q4  1.0 (0.76-1.37) 1.0 (0.61-1.75) 1.0 (0.74-1.31) 1.2 (0.71-1.95) 
p-value 0.82 0.65 0.39 0.81 
Palmitic acid (16:0), g     
Q1  1.0 (0.75-1.31) 1.1 (0.67-1.79) 1.2 (0.90-1.53) 0.7 (0.43-1.18) 
Q2-3  1 1 1 1 
Q4 0.9 (0.64-1.18) 1.2 (0.73-2.11) 1.1 (0.84-1.48) 0.8 (0.50-1.32) 
p-value 0.63 0.75 0.49 0.36 
Stearic acid (18:0), mg     
Q1 1.2 (0.93-1.62) 1.3 (0.78-2.03) 1.3 (1.00-1.71) 0.9 (0.57-1.45) 
Q2-3 1 1 1 1 
Q4 0.8 (0.62-1.15) 0.9 (0.53-1.59) 1.1 (0.84-1.48) 0.8 (0.48-1.29) 
p-value 0.11 0.53 0.16 0.63 
MUFA, g     
Q1  1.0 (0.80-1.39) 1.1 (0.70-1.84) 1.0 (0.78-1.34) 0.8 (0.50-1.33) 
Q2-3 1 1 1 1 
Q4 0.8 (0.61-1.11) 0.9 (0.54-1.61) 1.0 (0.75-1.33) 0.8 (0.50-1.37) 
p-value 0.28 0.80 0.99 0.61 
Sum of 18:1 isomers, g     
Q1 1.0 (0.79-1.39) 1.2 (0.71-1.87) 1.0 (0.78-1.34) 0.8 (0.47-1.28) 
Q2-3 1 1 1 1 
Q4 0.8 (0.61-1.10) 0.9 (0.55-1.63) 1.0 (0.75-1.33) 0.8 (0.50-1.36) 
p-value 0.28 0.79 0.99 0.57 
PUFA, g     
Q1 1.2 (0.89-1.57) 1.6 (0.98-2.75) 1.1 (0.84-1.44) 1.2 (0.73-1.87) 
Q2-3 1 1 1 1 
Q4 0.9 (0.66-1.23) 1.2 (0.70-2.11) 0.9 (0.70-1.22) 1.0 (0.61-1.69) 
p-value 0.30 0.22 0.55 0.81 
 n-3 PUFA, g     
Q1 1.0 (0.76-1.36) 1.3 (0.75-2.12) 1.3 (0.96-1.64) 1.9 (1.17-2.93) 
Q2-3 1 1 1 1 
Q4 0.9 (0.69-1.24) 1.1 (0.63-1.81) 1.1 (0.79-1.39) 1.7 (1.02-2.73) 
p-value 0.83 0.71 0.26 0.02 
α-Linolenic acid (18:3n-3), g     
Q1 1.0 (0.74-1.32) 1.4 (0.79-2.30) 1.1 (0.84-1.45) 1.5 (0.91-2.33) 
Q2-3 1 1 1 1 
Q4  1.0 (0.78-1.41) 1.1 (0.68-1.92) 1.0 (0.77-1.35) 1.2 (0.73-1.99) 
p-value 0.94 0.57 0.77 0.30 
EPA (20:5n-3), mg     
Q1 0.8 (0.62-1.13) 0.5 (0.27-0.94) 1.1 (0.80-1.39) 0.9 (0.58-1.47) 
Q2-3 1 1 1 1 
Q4  1.0 (0.75-1.35) 1.0 (0.61-1.70) 0.9 (0.68-1.19) 0.8 (0.48-1.31) 
p-value 0.45 0.03 0.61 0.65 
DHA (22:6n-3), mg     
Q1 0.9 (0.65-1.20) 0.6 (0.31-1.06) 1.1 (0.81-1.40) 0.9 (0.56-1.44) 
Q2-3 1 1 1 1 
Q4  1.1 (0.82-1.47) 1.0 (0.61-1.70) 0.9 (0.69-1.20) 0.8 (0.48-1.30) 
p-value 0.48 0.12 0.63 0.63 
n-6 PUFA, g     
Q1 1.1 (0.85-1.50) 1.5 (0.88-2.42) 0.9 (0.71-1.22) 1.0 (0.62-1.60) 
Q2-3 1 1 1 1 
Q4  0.8 (0.56-1.02) 1.0 (0.56-1.68) 0.8 (0.64-1.12) 0.8 (0.48-1.35) 
p-value 0.048 0.36 0.47 0.68 
Linoleic acid (18:2n-6), g      
Q1 1.2 (0.89-1.57) 1.6 (0.95-2.67) 1.0 (0.73-1.25) 1.1 (0.66-1.71) 
Q2-3 1 1 1 1 
Q4  0.8 (0.61-1.11) 1.0 (0.60-1.80) 0.9 (0.66-1.16) 0.9 (0.55-1.52) 
p-value 0.11 0.26 0.63 0.87 
Arachidonic acid (20:4n-6), 
mg 
    
Q1 0.8 (0.61-1.13) 0.7 (0.40-1.26) 1.0 (0.77-1.34) 1.0 (0.59-1.59) 
Q2-3 1 1 1 1 
Q4  0.7 (0.55-0.98) 0.8 (0.46-1.32) 0.9 (0.68-1.19) 1.0 (0.63-1.61) 
p-value 0.09 0.39 0.71 0.99 
γ-Linoleic acid (18:3n-6), mg     
Q1 0.9 (0.70-1.22) 1.2 (0.73-1.82) 1.1 (0.85-1.46) 0.9 (0.55-1.43) 
Q2-3 1 1 1 1 
Q4  0.9 (0.68-1.24) 0.8 (0.46-1.52) 1.0 (0.74-1.31) 1.2 (0.72-1.96) 
p-value 0.79 0.56 0.68 0.64 
Conjugated linoleic acid 
(18:2n-6), mg 
    
Q1 0.8 (0.59-1.07) 0.8 (0.50-1.32) 1.0 (0.79-1.35) 0.8 (0.51-1.33) 
Q2-3 1 1 1 1 
Q4  1.0 (0.71-1.30) 0.9 (0.48-1.60) 1.0 (0.72-1.28) 1.0 (0.61-1.66) 
p-value 0.28 0.68 0.91 0.71 
Trans fatty acids, g     
Q1 1.1 (0.83-1.48) 1.1 (0.70-1.87) 1.1 (0.85-1.47) 1.0 (0.61-1.63) 
Q2-3 1 1 1 1 
Q4  1.4 (1.02-1.82) 1.5 (0.85-2.51) 1.0 (0.80-1.39) 1.2 (0.73-1.95) 
p-value 0.13 0.44 0.72 0.78 
Ratios     
 n-6:n-3     
Q1 1.0 (0.74-1.31) 0.8 (0.51-1.40) 1.4 (1.07-1.81) 2.0 (1.27-3.20) 
Q2-3 1 1 1 1 
Q4  0.9 (0.69-1.26) 1.0 (0.61-1.78) 1.1 (0.83-1.45) 1.7 (1.03-2.73) 
p-value 0.91 0.75 0.07 0.01 
Linoleic acid (18:2n-6):α-
Linolenic acid (18:3n-3) 
    
Q1 1.1 (0.82-1.46) 1.0 (0.57-1.61) 1.4 (1.05-1.81) 1.8 (1.12-2.93) 
Q2-3 1 1 1 1 
Q4  0.9 (0.66-1.19) 1.0 (0.58-1.66) 1.2 (0.91-1.58) 1.7 (1.07-2.84) 
p-value 0.46 0.99 0.07 0.02 
Arachidonic acid (20:4n-
6):DHA+EPA 
    
Q1 1.1 (0.78-1.41) 1.0 (0.60-1.57) 1.0 (0.78-1.36) 1.0 (0.62-1.64) 
Q2-3 1 1 1 1 
Q4  0.8 (0.58-1.07) 0.5 (0.26-0.88) 0.9 (0.71-1.23) 0.8 (0.46-1.26) 
p-value 0.20 0.02 0.83 0.49 
The OR (95% CI) are from generalized estimating equations adjusted for maternal early pregnancy 
BMI, gestational weight gain rate, time of the first weight measurement (≤10.0 vs >10 weeks of 
pregnancy) glucose intolerance diet, education, smoking during pregnancy, and duration of 
breastfeeding. p-values are based on type 3 Score test.  The fatty acid variables used in statistical 
analysis were energy-adjusted using Willett’s residual method after logarithmic transformation. The 
sum of the 18:1 isomers consists mainly of oleic acid (18:1 n-9) and cis-vaccenic acid (18:1 n-7). 
IOTF = International Obesity Task Force; E% = percent of daily energy intake; SFA = Saturated 
fatty acid; MUFA = Monounsaturated fatty acid; PUFA = Polyunsaturated fatty acid; DHA = 
Docosahexaenoic acid; EPA = Eicosapentaenoic acid; Q1 =1
st quartile; Q2-3 = the 2 middle quartiles; 
Q4 = 4
th quartile.  
 
 
 
Figure S1. Flowchart of the DIPP Nutrition Study recruitment and formation of the present study 
population. 
 
aNo FFQ (food frequency questionnaire) or FFQ with >10 missing items. 
bNo data on birth size or at least one weight and height measure between 2 and 7 years (± 3 months) 
 
  
Invited to DIPP Nutrition Study  
(n = 7782)
Singletons in follow-up
(n = 5840)
Analysis cohort 
(n = 3807)
Declined (n = 1699)
Missing growth datab (n = 936)
Enrolled for follow-up 
(n = 6083)
Twins (n = 237)
Triplets (n = 6)
Mothers with FFQ data
(n = 4743 )
Missing FFQ dataa (n = 1097)
 
 
Table S1. Food frequency questionnaire-based dietary intake of carbohydrates, proteins and fats, 
with emphasis on fatty acids in 3807 mothers during eighth month of pregnancy, the DIPP Nutrition 
Study, Finland.  
 Absolute intake Percent of total 
energy intake, E% 
 Mean (SD) Mean (SD) 
Total energy intake, kJ/day 11623 (3364) 
 
 
Carbohydrates, g 327 (101) 
 
50.6 (5.1) 
Proteins, g 109 (32) 16.1 (2.2) 
Fats (total), g 105 (36) 33.2 (4.8) 
Fats, triacylglycerols, g 98 (34)  
SFA, g 43.3 (16.7) 13.7 (2.7) 
Myristic acid(14:0), g 4.8 (2.0)  
Pentadecanoid acid (15:0), mg 618 (284)  
Palmitic acid (16:0), g 20.3 (7.5)  
Stearic acid (18:0), mg 10.6 (4.3)  
MUFA, g 35.6 (12.4) 11.3 (1.9) 
Sum of 18:1 isomers, g 32.7 (11.5)  
PUFA, g 13.7 (5.0) 4.4 (1.0) 
n-3 PUFA, g 3.1 (1.2) 1.0 (0.3) 
α-Linolenic acid (18:3n-3), g 2.5 (1.0)  
EPA (20:5n-3), mg 98.4 (84.8)  
DHA (22:6n-3), mg 261 (220)  
n-6 PUFA, g 10.3 (3.8) 3.3 (0.8) 
Linoleic acid (18:2n-6), g  10.0 (3.7)  
Arachidonic acid (20:4n-6), mg 97.3 (41.2)  
γ-Linoleic acid (18:3n-6), mg 57.5 (32.2)  
Conjugated linoleic acid (18:2n-6), mg 181 (80.8)  
Trans fatty acids, g 1.3 (0.6)  
Ratios   
n-6:n-3 3.5 (0.8)  
Linoleic acid (18:2n-6):α-Linolenic acid 
(18:3n-3) 
4.2 (1.0)  
Arachidonic acid (20:4n-6):DHA+EPA 0.43 (0.36)  
SFA = Saturated fatty acid; MUFA = Monounsaturated fatty acid; PUFA = Polyunsaturated fatty acid; DHA 
= Docosahexaenoic acid; EPA = Eicosapentaenoic acid; Total energy and carbohydrates include the 
calculated energy from fibre. Sum of 18:1 isomers consists mainly of oleic acid (18:1 n-9) and cis-vaccenic 
acid (18:1 n-7). 
 
 
  
 
 
Table S2. Unadjusted odds ratios (OR) for offspring overweight (including obesity) and obesity 
based on IOTF criteria from ages of 2 to 7 years according to quartiles of maternal energy and fatty 
acid intake during pregnancy in 3807 mother-child pairs, the DIPP Nutrition Study, Finland. 
 Boys (n=1984) Girls (n=1823) 
 Overweight Obesity Overweight Obesity 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Total energy intake, kJ     
Q1 <9300 1.0 (0.78-1.35) 1.1 (0.65-1.72) 1.2 (0.92-1.53) 1.4 (0.87-2.10) 
Q2-3 9300-13400 1 1 1 1 
Q4 > 13400 1.3 (0.99-1.69) 1.4 (0.85-2.20) 1.07 (0.84-1.37) 1.0 (0.63-1.55) 
p-value 0.19 0.48 0.43 0.40 
Carbohydrates, E%     
Q1 <47.2 0.8 (0.61-1.08) 0.9 (0.56-1.54) 1.0 (0.80-1.34) 1.0 (0.63-1.54) 
Q2-3 47.2-53.8 1 1 1 1 
Q4 > 53.8 0.9 (0.72-1.23) 1.0 (0.62-1.56) 1.2 (0.96-1.58) 1.2 (0.77-1.86) 
p-value 0.33 0.96 0.26 0.74 
Proteins, E%     
Q1 <14.7 0.9 (0.67-1.16) 0.9 (0.54-1.47) 1.4 (1.06-1.75) 1.4 (0.90-2.20) 
Q2-3 14.7-17.5 1 1 1 1 
Q4 > 17.5 1.0 (0.80-1.36) 1.2 (0.78-1.97) 1.2 (0.97-1.60) 1.3 (0.81-1.93) 
p-value 0.52 0.52 0.04 0.30 
Fats, E%     
Q1 <30.0 1.0 (0.74-1.26) 0.9 (0.55-1.43) 1.1 (0.87-1.43) 0.9 (0.57-1.41) 
Q2-3 30.0-36.4 1 1  1 
Q4 > 36.4 0.8 (0.60-1.06) 1.0 (0.63-1.63) 1.0 (0.79-1.32) 0.9 (0.59-1.45) 
p-value 0.26 0.85 0.68 0.88 
SFA, g     
Q1 1.0 (0.75-1.27) 0.9 (0.57-1.47) 1.1 (0.85-1.38) 0.7 (0.44-1.15) 
Q2-3  1 1 1 1 
Q4 > 0.9 (0.69-1.20) 1.1 (0.66-1.73) 1.0 (0.76-1.27) 0.8 (0.51-1.27) 
p-value 0.78 0.85 0.77 0.31 
Myristic acid (14:0), g     
Q1 1.0 (0.76-1.30) 0.9 (0.56-1.46) 1.3 (0.98-1.59) 1.2 (0.77-1.85) 
Q2-3  1 1 1 1 
Q4  1.0 (0.73-1.27) 1.0 (0.60-1.60) 1.0 (0.74-1.25) 1.1 (0.69-1.70) 
p-value 0.96 0.91 0.13 0.76 
Palmitic acid (16:0), g     
Q1 0.9 (0.72-1.23) 1.0 (0.61-1.58) 1.1 (0.86-1.40) 0.7 (0.42-1.09) 
Q2-3  1 1 1 1 
Q4  0.9 (0.66-1.16) 1.3 (0.81-2.09) 1.1 (0.82-1.38) 0.8 (0.51-1.25) 
p-value 0.65 0.55 0.75 0.22 
Stearic acid (18:0), mg     
Q1 1.1 (0.87-1.47) 1.0 (0.65-1.62) 1.2 (0.97-1.58) 0.9 (0.54-1.34) 
Q2-3  1 1 1 1 
Q4  0.9 (0.70-1.24) 1.1 (0.70-1.89) 1.2 (0.93-1.54) 1.0 (0.64-1.56) 
p-value 0.46 0.87 0.18 0.76 
MUFA, g     
Q1 1.1 (0.83-1.41) 1.1 (0.70-1.76) 1.1 (0.83-1.37) 1.0 (0.62-1.53) 
Q2-3  1 1 1 1 
Q4  0.8 (0.64-1.11) 0.9 (0.56-1.53) 1.1 (0.86-1.44) 1.0 (0.61-1.50) 
p-value 0.26 0.81 0.70 0.98 
Sum of 18:1 isomers, g     
Q1 1.1 (0.83-1.41) 1.1 (0.71-1.79) 1.1 (0.87-1.43) 1.0 (0.66-1.60) 
Q2-3  1 1  1 
 
 
Q4  0.9 (0.64-1.12) 1.0 (0.58-1.57) 1.1 (0.87-1.46) 1.0 (0.63-1.527 
p-value 0.29 0.87 0.56 0.74 
PUFA, g     
Q1 1.2 (0.94-1.60) 1.7 (1.07-2.69) 1.1 (0.86-1.42) 1.4 (0.94-2.22) 
Q2-3  1 1 1 1 
Q4  0.9 (0.70-1.22) 1.2 (0.73-1.94) 1.0 (0.75-1.25) 1.1 (0.71-1.76) 
p-value 0.19 0.13 0.62 0.31 
 n-3 PUFA, g     
Q1 1.1 (0.81-1.39) 1.3 (0.82-2.13) 1.3 (1.00-1.64) 2.2 (1.42-3.37) 
Q2-3  1 1 1 1 
Q4  0.9 (0.67-1.15) 1.0 (0.61-1.58) 1.0 (0.80-1.35) 1.6 (1.04-2.60) 
p-value 0.46 0.50 0.15 0.003 
α-Linolenic acid (18:3n-3), g     
Q1 1.0 (0.73-1.26) 1.2 (0.73-1.97) 1.15 (0.89-1.47) 1.6 (1.06-2.52) 
Q2-3 1 1 1 1 
Q4  1.0 (0.76-1.30) 1.1 (0.67-1.67) 1.05 (0.81-1.35) 1.2 (0.79-1.97) 
p-value 0.96 0.57 0.57 0.10 
EPA (20:5n-3), mg     
Q1 0.9 (0.71-1.22) 0.8 (0.48-1.32) 1.03 (0.80-1.33) 1.0 (0.65-1.57) 
Q2-3 1 1 1 1 
Q4  0.8 (0.63-1.09) 0.8 (0.50-1.32) 0.8 (0.61-1.02) 0.7 (0.45-1.14) 
p-value 0.37 0.56 0.11 0.27 
DHA (22:6n-3), mg     
Q1 1.0 (0.76-1.33) 0.9 (0.53-1.46) 1.05 (0.82-1.35) 1.0 (0.65-1.55) 
Q2-3 1 1 1 1 
Q4  0.9 (0.70-1.21) 0.8 (0.51-1.34) 0.8 (0.62-1.04) 0.7 (0.43-1.11) 
p-value 0.80 0.71 0.13 0.22 
n-6 PUFA, g     
Q1 1.2 (0.89-1.53) 1.5 (0.96-2.41) 1.0 (0.74-1.22) 1.3 (0.82-1.94) 
Q2-3 1 1 1 1 
Q4  0.8 (0.62-1.09) 1.0 (0.62-1.69) 0.9 (0.70-1.18) 1.0 (0.61-1.54) 
p-value 0.10 0.24 0.76 0.54 
Linoleic acid (18:2n-6), g      
Q1 1.2 (0.94-1.60) 1.7 (1.05-2.64) 1.0 (0.75-1.23) 1.3 (0.84-1.99) 
Q2-3 1 1 1 1 
Q4  0.9 (0.67-1.17) 1.1 (0.67-1.81) 0.9 (0.71-1.19) 1.0 (0.64-1.62) 
p-value 0.13 0.14 0.81 0.52 
Arachidonic acid (20:4n-6), 
mg 
    
Q1 0.9 (0.67-1.17) 0.8 (0.49-1.31) 1.0 (0.80-1.33) 1.2 (0.77-1.86) 
Q2-3 1 1 1 1 
Q4  0.7 (0.57-0.99) 0.7 (0.44-1.19) 1.0 (0.75-1.24) 1.1 (0.70-1.71) 
p-value 0.10 0.37 0.91 0.74 
γ-Linoleic acid (18:3n-6), mg     
Q1 1.1 (0.81-1.4) 1.3 (0.85-2.05) 1.2 (0.94-1.54) 0.9 (0.60-1.46) 
Q2-3 1 1 1 1 
Q4  0.9 (0.70-1.23) 0.9 (0.54-1.55) 1.0 (0.73-1.23) 1.1 (0.70-1.68) 
p-value 0.70 0.39 0.23 0.86 
Conjugated linoleic acid 
(18:2n-6), mg 
    
Q1 0.9 (0.71-1.22) 1.1 (0.66-1.67) 1.1 (0.87-1.42) 0.9 (0.58-1.44) 
Q2-3 1 1 1 1 
Q4  1.0 (0.73-1.27) 1.0 (0.61-1.72) 1.0 (0.74-1.25) 1.0 (0.66-1.59) 
p-value 0.87 0.98 0.57 0.89 
Trans fatty acids, g     
 
 
Q1 1.2 (0.93-1.60) 1.3 (0.82-2.07) 1.2 (0.92-1.50) 1.1 (0.70-1.72) 
Q2-3 1 1 1 1 
Q4  1.3 (1.03-1.77) 1.5 (0.93-2.45) 1.1 (0.82-1.36) 1.2 (0.78-1.89) 
p-value 0.08 0.23 0.46 0.69 
Ratios     
 n-6:n-3     
Q1 0.9 (0.66-1.13) 0.8 (0.47-1.22) 1.3 (1.05-1.71) 1.9 (1.20-2.85) 
Q2-3 1 1 1 1 
Q4  1.0 (0.76-1.32) 1.1 (0.70-1.82) 1.2 (0.89-1.50) 1.8 (1.12-2.81) 
p-value 0.52 0.32 0.07 0.008 
Linoleic acid (18:2n-6):α-
Linolenic acid (18:3n-3) 
    
Q1 1.0 (0.76-1.29) 1.0 (0.63-1.58) 1.4 (1.09-1.78) 1.7 (1.13-2.69) 
Q2-3 1 1 1 1 
Q4  0.8 (0.64-1.12) 0.9 (0.56-1.55) 1.2 (0.95-1.57) 1.8 (1.13-2.80) 
p-value 0.44 0.96 0.03 0.01 
Arachidonic acid (20:4n-
6):DHA+EPA 
    
Q1 0.9 (0.65-1.12) 0.7 (0.47-1.19) 0.9 (0.69-1.13) 0.8 (0.54-1.31) 
Q2-3 1 1 1 1 
Q4  0.9 (0.70-1.21) 0.7 (0.41-1.14) 0.9 (0.73-1.22) 0.9 (0.54-1.40) 
p-value 0.49 0.23 0.60 0.69 
The OR (95% CI) are from generalized estimating equations. p-values are based on type 3 Score 
test.  The fatty acid variables used in statistical analysis were energy-adjusted using Willett’s 
residual method after logarithmic transformation. The sum of the 18:1 isomers consists mainly of 
oleic acid (18:1 n-9) and cis-vaccenic acid (18:1 n-7). IOTF = International Obesity Task Force; 
E% = percent of daily energy intake; SFA = Saturated fatty acid; MUFA = Monounsaturated fatty 
acid; PUFA = Polyunsaturated fatty acid; DHA = Docosahexaenoic acid; EPA = Eicosapentaenoic 
acid. Q1 =1
st quartile; Q2-3 = the 2 middle quartiles; Q4 = 4
th quartile.  
  
 
 
Table S3. Adjusted odds ratios (OR) for offspring overweight (including obesity) and obesity based 
on IOTF criteria from the ages of 2 to 7 years according to tertiles of maternal energy and fatty acid 
intake during pregnancy in 3807 mother-child pairs, the DIPP Nutrition Study, Finland. 
 Boys (n=1984) Girls (n=1823) 
 Overweight Obesity Overweight Obesity 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Total energy intake, kJ     
T1 < 10000 1.2 (0.89-1.60) 1.0 (0.56-1.61) 1.1 (0.83-1.46) 1.3 (0.81-2.10) 
T2 10000-12450 1 1 1 1 
T3  > 12450 1.4 (1.05-1.87) 1.5 (0.90-2.43) 0.9 (0.69-1.19) 0.7 (0.42-1.16) 
p-value 0.07 0.24 0.37 0.048 
Carbohydrates, E%     
T1 < 48.4 1.0 (0.76-1.37) 1.1 (0.68-1.85) 1.2 (0.90-1.60) 1.1 (0.67-1.80) 
T2 48.4-52.6 1 1 1 1 
T3  > 52.6 1.0 (0.77-1.37) 0.9 (0.53-1.47) 1.5 (1.14-1.97) 1.2 (0.75-1.97) 
p-value 0.98 0.66 0.02 0.76 
Proteins, E%     
T1 < 15.1 1.0 (0.71-1.30) 0.9 (0.55-1.63) 1.4 (1.05- 1.82) 1.5 (0.89-2.51) 
T2 15.1-17.0 1 1 1 1 
T3  > 17.0 1.1 (0.83-1.48) 1.3 (0.79-2.23) 1.2 (0.94-1.65) 1.7 (1.03-2.73) 
p-value 0.64 0.44 0.06 0.08 
Fats, E%     
T1 < 31.1 1.1 (0.85-1.50) 1.1 (0.70-1.85) 1.3 (0.96-1.65) 1.1 (0.65-1.70) 
T2 31.1-35.1 1 1 1 1 
T3  > 35.1 0.9 (0.67-1.24) 1.0 (0.60-1.85) 1.1 (0.80-1.41) 1.0 (0.59-1.58) 
p-value 0.36 0.86 0.23 0.95 
SFA, g     
T1  1.0 (0.78-1.39) 1.1 (0.66-1.87) 1.2 (0.90-1.54) 0.8 (0.51-1.31) 
T2  1 1 1 1 
T3   0.9 (0.70-1.28) 1.1 (0.66-1.98) 1.0 (0.75-1.36) 0.8 (0.49-1.36) 
p-value 0.81 0.88 0.43 0.65 
Myristic acid (14:0), g     
T1  0.9 (0.68-1.22) 0.8 (0.47-1.29) 1.1 (0.82-1.41) 0.9 (0.57-1.52) 
T2  1 1 1 1 
T3   1.0 (0.76-1.38) 1.0 (0.62-1.75) 1.0 (0.78-1.38) 1.1 (0.65-1.71) 
p-value 0.71 0.46 0.86 0.91 
Palmitic acid (16:0), g     
T1  1.1 (0.85-1.53) 1.3 (0.77-2.29) 1.2 (0.92-1.58) 0.9 (0.58-1.51) 
T2  1 1 1 1 
T3   1.0 (0.74-1.36) 1.4 (0.82-2.52) 1.1 (0.80-1.43) 1.0 (0.60-1.61) 
p-value 0.59 0.38 0.42 0.96 
Stearic acid (18:0), mg     
T1  1.6 (0.87-1.54) 1.3 (0.79-2.24) 1.2 (0.90-1.57) 1.0 (0.59-1.57) 
T2  1 1 1 1 
T3   0.9 (0.67-1.23) 1.2 (0.71-2.12) 1.0 (0.77-1.37) 0.9 (0.56- 1.51) 
p-value 0.28 0.53 0.45 0.94 
MUFA, g     
T1  1.0 (0.76-1.34) 1.1 (0.64-1.73) 1.0 (0.75-1.30) 0.9 (0.53-1.38) 
T2  1 1 1 1 
T3   0.8 (0.61-1.12) 1.0 (0.56-1.65) 1.0 (0.74-1.29) 1.0 (0.59-1.57) 
p-value 0.35 0.95 0.99 0.80 
Sum of 18:1 isomers, g     
T1  0.9 (0.71-1.25) 1.0 (0.62-1.68) 1.0 (0.79-1.35) 1.0 (0.59-1.55) 
T2  1 1 1 1 
 
 
T3   0.8 (0.58-1.06) 0.9 (0.56-1.61) 1.0 (0.78-1.36) 1.1 (0.65-1.73) 
p-value 0.25 0.96 0.97 0.93 
PUFA, g     
T1  1.2 (0.90-1.59) 1.4 (0.87-2.40) 1.2 (0.88-1.52) 1.18 (0.72-1.92) 
T2  1 1 1 1 
T3   0.9 (0.68-1.23) 1.1 (0.65-1.89) 1.0 (0.79-1.37) 1.1 (0.66-1.86) 
p-value 0.20 0.38 0.58 0.81 
 n-3 PUFA, g     
T1  1.1 (0.83-1.50) 1.5 (0.87-2.50) 1.1 (0.81-1.40) 1.3 (0.80- 2.07) 
T2  1 1 1 1 
T3   0.9 (0.69-1.26) 1.2 (0.68-1.98) 1.0 (0.79-1.38) 1.2 (0.73-2.01) 
p-value 0.47 0.36 0.89 0.56 
α-Linolenic acid (18:3n-3), g     
T1  1.1 (0.80-1.41) 1.4 (0.82-2.28) 1.0 (0.79-1.36) 1.4 (0.88-2.35) 
T2  1 1 1 1 
T3   1.0 (0.74-1.33) 1.1 (0.65-1.81) 1.0 (0.78-1.35) 1.3 (0.81-2.23) 
p-value 0.89 0.49 0.97 0.29 
EPA (20:5n-3), mg     
T1  0.9 (0.69-1.24) 0.7 (0.38-1.12) 1.0 (0.78-1.36) 0.9 (0.54-1.38) 
T2  1 1 1 1 
T3   1.0 (0.74-1.34) 1.0 (0.63-1.69) 0.9 (0.68-1.19) 0.7 (0.41-1.13) 
p-value 0.84 0.16 0.59 0.35 
DHA (22:6n-3), mg     
T1  0.8 (0.63-1.13) 0.5 (0.29-0.89) 1.161 0.881 
1.532 
1.1 (0.69-1.82) 
T2  1 1 1 1 
T3   0.9 (0.71-1.27) 1.0 (0.60-1.58) 1.0 (0.77-1.34) 1.0 (0.59-1.63) 
p-value 0.49 0.02 0.52 0.85 
n-6 PUFA, g     
T1  1.1 (0.84-1.49) 1.5 (0.91-2.53) 1.0 (0.74-1.27) 0.9 (0.56-1.49) 
T2  1 1 1 1 
T3   0.8 (0.63-1.14) 1.1 (0.66-1.94) 0.9 (0.69-1.21) 0.8 (0.50-1.37) 
p-value 0.17 0.31 0.81 0.75 
Linoleic acid (18:2n-6), g      
T1  1.1 (0.85-1.50) 1.4 (0.85-2.37) 1.0 (0.78-1.35) 1.1 (0.65-1.70) 
T2  1 1 1 1 
T3   0.8 (0.62-1.13) 1.0 (0.60-1.75) 0.9 (0.69-1.21) 0.9 (0.53-1.46) 
p-value 0.13 0.38 0.70 0.74 
Arachidonic acid (20:4n-6), 
mg 
    
T1  0.9 (0.65-1.15) 0.7 (0.43-1.20) 1.0 (0.73-1.25) 1.0 (0.60-1.59 
T2  1 1 1 1 
T3   0.7 (0.52-0.93) 0.6 (0.36-1.03) 0.8 (0.61- 1.05) 0.9 (0.53- 1.38) 
p-value 0.046 0.15 0.25 0.80 
γ-Linoleic acid (18:3n-6), mg     
T1  1.2 (0.88-1.59) 1.5 (0.88-2.46) 1.1 (0.86-1.49) 0.8 (0.50-1.33) 
T2  1 1 1 1 
T3   1.3 (0.94-1.73) 1.6 (0.91-2.81) 1.1 (0.85-1.49) 1.2 (0.73-1.94) 
p-value 0.27 0.18 0.60 0.37 
Conjugated linoleic acid 
(18:2n-6), mg 
    
T1  0.9 (0.70-1.25) 0.7 (0.46-1.18) 1.1 (0.86-1.47) 1.2 (0.70-1.95) 
T2  1 1 1 1 
T3   1.1 (0.82-1.48) 1.0 (0.58-1.65) 1.2 (0.89-1.54) 1.6 (0.99-2.67) 
p-value 0.55 0.38 0.54 0.16 
 
 
Trans fatty acids, g     
Q1 0.9 1.2 (0.88-1.59) 1.0 (0.63-1.69) 1.1 (0.80-1.39) 0.8 (0.50-1.36) 
Q2-3 0.9-1.6 1 1 1 1 
Q4  1.6 1.4 (1.07-1.95) 1.4 (0.83-2.40) 1.1 (0.84-1.45) 1.0 (0.63-1.64) 
p-value 0.06 0.43 0.77 0.68 
Ratios     
 n-6:n-3     
T1  1.2 (0.87-1.54) 1.0 (0.63-1.67) 1.3 (1.02-1.76) 2.5 (1.45-4.19) 
T2  1 1 1 1 
T3   0.9 (0.67-1.23) 0.9 (0.50-1.55) 1.3 (1.01- 1.74) 2.2 (1.32-3.78) 
p-value 0.27 0.86 0.047 0.0006 
Linoleic acid (18:2n-6):α-
Linolenic acid (18:3n-3) 
    
T1  1.2 (0.91-1.63) 1.0 (0.59-1.61) 1.1 (0.84-1.44) 1.2 (0.77-1.98) 
T2  1 1 1 1 
T3   1.0 (0.72-1.31) 1.0 (0.61-1.79) 1.0 (0.77-1.33) 1.2 (0.72-1.92) 
p-value 0.25 0.97 0.73 0.66 
Arachidonic acid (20:4n-
6):DHA+EPA 
    
T1  1.1 (0.80-1.42) 1.2 (0.75-1.91) 1.3 (0.95-1.68) 1.5 (0.87-2.43) 
T2  1 1 1 1 
T3   0.8 (0.60-1.10) 0.6 (0.32-1.02) 1.2 (0.90-1.56) 1.2 (0.76 1.98) 
p-value 0.20 0.04 0.23 0.36 
The OR (95% CI) are from generalized estimating equations adjusted for maternal early pregnancy 
BMI, gestational weight gain rate, time of the first weight measurement (≤10.0 vs >10 weeks of 
pregnancy) glucose intolerance diet, education, smoking during pregnancy, and duration of 
breastfeeding. p-values are based on type 3 Score test. The fatty acid variables used in statistical 
analysis were energy-adjusted using Willett’s residual method after logarithmic transformation. The 
sum of the 18:1 isomers consists mainly of oleic acid (18:1 n-9) and cis-vaccenic acid (18:1 n-7). 
IOTF = International Obesity Task Force; E% = percent of daily energy intake; SFA = Saturated 
fatty acid; MUFA = Monounsaturated fatty acid; PUFA = Polyunsaturated fatty acid; DHA = 
Docosahexaenoic acid; EPA = Eicosapentaenoic acid; T1 =1
st tertile; T2 = 2
nd tertile; T3 = 3
rd tertile.  
 
 
 
 
 
  
 
 
Table S4. Adjusted odds ratios (OR) for offspring overweight (including obesity) and obesity based 
on WHO criteria from the ages of 2 to 7 years according to quartiles of maternal energy and fatty 
acid intake during pregnancy in 3807 mother-child pairs, the DIPP Nutrition Study, Finland. 
 Boys (n=1984) Girls (n=1823) 
 Overweight Obesity Overweight Obesity 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Total energy intake, kJ     
Q1 <9300 0.9 (0.76-1.16) 1.3 (0.93-1.87) 1.1 (0.88-1.34) 1.2 (0.81-1.70) 
Q2-3 9300-13400 1 1 1 1 
Q4 > 13400 1.2 (0.97-1.44) 1.5 (1.07-2.13) 1.1 (0.90-1.33) 0.9 (0.66-1.29) 
p-value 0.15  0.06 0.58 0.52 
Carbohydrates, E%     
Q1 <47.2 0.9 (0.70-1.05) 0.8 (0.58-1.20) 1.1 (0.88-1.32) 1.1 (0.76-1.56) 
Q2-3 47.2-53.8 1 1 1 1 
Q4 > 53.8 0.9 (0.78-1.15) 1.0 (0.68-1.38) 1.1 (0.87-1.31) 1.2 (0.86-1.71) 
p-value 0.32 0.59 0.70 0.55 
Proteins, E%     
Q1 <14.7 1.0 (0.81-1.22) 0.9 (0.62-1.32) 1.4 (1.17-1.74) 1.5 (1.05-2.13) 
Q2-3 14.7-17.5 1 1 1 1 
Q4 > 17.5 1.0 (0.81-1.21) 1.1 (0.78-1.56) 1.1 (0.94-1.41) 1.3 (0.89-1.78) 
p-value 0.99 0.65 0.003 0.09 
Fats, E%     
Q1 <30.0 1.1 (0.88-1.30) 1.0 (0.71-1.38) 1.0 (0.78-1.17) 0.8 (0.59-1.17) 
Q2-3 30.0-36.4 1 1 1 1 
Q4 > 36.4 1.0 (0.78-1.17) 0.9 (0.60-1.25) 1.1 (0.92-1.38) 0.9 (0.63-1.34) 
p-value 0.63 0.71  0.55 
SFA, g     
Q1 1.0 (0.87-1.27) 0.9 (0.68-1.32) 1.0 (0.79-1.19) 0.8 (0.58-1.15) 
Q2-3 1 1 1 1 
Q4 1.0 (0.82-1.24) 0.8 (0.58-1.21) 1.1 (0.87-1.30) 1.0 (0.66-1.38) 
p-value 0.88 0.63 0.74 0.50 
Myristic acid (14:0), g     
Q1 0.9 (0.74-1.10) 0.8 (0.60-1.19) 1.0 (0.82-1.23) 1.0 (0.71-1.41) 
Q2-3 1 1 1 1 
Q4 1.0 (0.80-1.20) 0.9 (0.65-1.34) 1.0 (0.81-1.22) 1.0 (0.72-1.53) 
p-value 0.59 0.62 0.99 0.97 
Palmitic acid (16:0), g     
Q1 1.0 (0.87-1.28) 1.0 (0.73-1.41) 1.0 (0.79-1.19) 0.8 (0.54-1.09) 
Q2-3 1 1 1 1 
Q4 0.9 (0.74-1.12) 0.9 (0.60-1.24) 1.1 (0.89-1.33) 1.0 (0.67-1.39) 
p-value 0.43 0.67 0.60 0.30 
Stearic acid (18:0), mg     
Q1 1.2 (0.96-1.42) 1.3 (0.91-1.78) 1.1 (0.88-1.33) 0.9 (0.67-1.32) 
Q2-3 1 1 1 1 
Q4 0.9 (0.74-1.13) 0.9 (0.62-1.29) 1.2 (0.95-1.43) 0.9 (0.64-1.35) 
p-value 0.12 0.23 0.32 0.90 
MUFA, g     
Q1 1.2 (0.95-1.41) 1.1 (0.75-1.48) 1.0 (0.80-1.20) 0.9 (0.66-1.30) 
Q2-3 1 1 1 1 
Q4 1.0 (0.85-1.27) 0.8 (0.59-1.20) 1.2 (0.96-1.44) 0.9 (0.64-1.38) 
p-value 0.37 0.49 0.24 0.89 
Sum of 18:1 isomers, g     
Q1 1.1 (0.94-1.39) 1.1 (0.79-1.54) 1.0 (0.82-1.24) 0.9 (0.62-1.25) 
Q2-3 1 1 1 1 
 
 
Q4 1.0 (0.83-1.24) 0.8 (0.58-1.19) 1.2 (0.99-1.48) 0.9 (0.63-1.35) 
p-value 0.41 0.38 0.17 0.75 
PUFA, g     
Q1 1.1 (0.89-1.33) 1.1 (0.79-1.60) 1.0 (0.83-1.24) 1.1 (0.76-1.51) 
Q2-3 1 1 1 1 
Q4 0.9 (0.73-1.10) 0.9 (0.64-1.33) 1.0 (0.81-1.22) 0.9 (0.61-1.30) 
p-value 0.28 0.65 0.99 0.68 
 n-3 PUFA, g     
Q1 1.0 (0.80-1.20) 0.9 (0.65-1.34) 1.0 (0.85-1.27) 1.5 (1.05-2.03) 
Q2-3 1 1 1 1 
Q4 0.9 (0.75-1.13) 0.9 (0.60-1.23) 1.0 (0.82-1.24) 1.3 (0.89-1.85) 
p-value 0.72 0.71 0.92 0.08 
α-Linolenic acid (18:3n-
3), g 
    
Q1 1.1 (0.90-1.32) 0.9 (0.65-1.35) 1.0 (0.80-1.20) 1.2 (0.85-1.69) 
Q2-3 1 1 1 1 
Q4 1.0 (0.84-1.27) 1.0 (0.68-1.38) 1.0 (0.84-1.27) 1.0 (0.68-1.43) 
p-value 0.75 0.94 0.90 0.54 
EPA (20:5n-3), mg     
Q1 0.9 (0.74-1.12) 0.7 (0.45-0.96) 1.0 (0.84-1.26) 0.9 (0.65-1.30) 
Q2-3 1 1 1 1 
Q4 1.0 (0.82-1.23) 1.0 (0.67-1.35) 0.9 (0.75-1.12) 0.8 (0.56-1.16) 
p-value 0.63 0.06 0.61 0.50 
DHA (22:6n-3), mg     
Q1 0.9 (0.77-1.17) 0.7 (0.45-0.97) 1.0 (0.85-1.27) 1.0 (0.67-1.35) 
Q2-3 1 1 1 1 
Q4 1.1 (0.87-1.29) 1.0 (0.72-1.42) 0.9 (0.73-1.10) 0.8 (0.59-1.21) 
p-value 0.68 0.06 0.47 0.64 
n-6 PUFA, g     
Q1 1.1 (0.92-1.38) 1.1 (0.79-1.59) 0.9 (0.75-1.13) 1.0 (0.69-1.37) 
Q2-3 1 1 1 1 
Q4 0.9 (0.72-1.07) 0.8 (0.53-1.11) 0.9 (0.7-1.16) 0.8 (0.53-1.12) 
p-value 0.10 0.17 0.69 0.35 
Linoleic acid (18:2n-6), g      
Q1 1.1 (0.94-1.40) 1.2 (0.81-1.63) 1.0 (0.79-1.18) 1.0 (0.70-1.41) 
Q2-3 1 1 1 1 
Q4 0.9 (0.74-1.10) 0.8 (0.56-1.16) 1.0 (0.80-1.20) 0.8 (0.57-1.21) 
p-value 0.13 0.23 0.94 0.58 
Arachidonic acid (20:4n-
6), mg 
    
Q1 1.0 (0.83-1.25) 0.8 (0.53-1.16) 0.9 (0.75-1.13) 1.1 (0.74-1.52) 
Q2-3 1 1 1 1 
Q4 0.8 (0.68-1.01) 0.8 (0.57-1.12) 0.9 (0.74-1.10) 1.1 (0.75-1.50) 
p-value 0.12 0.28 0.53 0.92 
γ-Linoleic acid (18:3n-6), 
mg 
    
Q1 0.9 (0.74-1.09) 0.9 (0.67-1.30) 1.0 (0.80-1.20) 0.9 (0.66-1.32) 
Q2-3 1 1 1 1 
Q4 0.9 (0.72-1.09) 0.7 (0.49-1.05) 1.0 (0.81-1.21) 1.0 (0.72-1.51) 
p-value 0.38 0.20 0.98 0.86 
Conjugated linoleic acid 
(18:2n-6), mg 
    
Q1 0.9 (0.71-1.06) 0.7 (0.49-1.00) 1.1 (0.86-1.29) 0.8 (0.57-1.14) 
Q2-3 1 1 1 1 
Q4 1.0 (0.78-1.18) 0.8 (0.54-1.14) 1.0 (0.85-1.28) 0.9 (0.63-1.34) 
 
 
p-value 0.36 0.10 0.86 0.47 
Trans fatty acids, g     
Q1 1.0 (0.84-1.24) 1.1 (0.75-1.51) 1.0 (0.78-1.18) 1.0 (0.74-1.48) 
Q2-3 1 1 1 1 
Q4 1.2 (0.95-1.43) 1.2 (0.87-1.77) 1.0 (0.83-1.23) 1.0 (0.72-1.51) 
p-value 0.34 0.52 0.90 0.96 
Ratios     
 n-6:n-3     
Q1 1.1 (0.88-1.29) 0.9 (0.64-1.24) 1.2 (0.96-1.45) 1.6 (1.14-2.27) 
Q2-3 1 1 1 1 
Q4 1.0 (0.78-1.18) 0.9 (0.66-1.37) 1.0 (0.83-1.23) 1.4 (1.00-2.02) 
p-value 0.69 0.78 0.27 0.02 
Linoleic acid (18:2n-6):α-
Linolenic acid (18:3n-3) 
    
Q1 1.1 (0.88-1.31) 1.0 (0.70-1.39) 1.3 (1.06-1.59) 1.4 (1.01-2.03) 
Q2-3 1 1 1 1 
Q4 1.0 (0.81-1.21) 0.9 (0.60-1.24) 1.1 (0.87-1.30) 1.4 (0.99-2.00) 
p-value 0.76 0.70 0.048 0.07 
Arachidonic acid (20:4n-
6):DHA+EPA 
    
Q1 1.1 (0.89-1.32) 1.1 (0.75-1.51) 0.9 (0.77-1.16) 0.9 (0.64-1.31) 
Q2-3 1 1 1 1 
Q4 0.9 (0.71-1.07) 0.7 (0.45-0.96) 1.0 (0.78-1.18) 0.7 (0.51-1.06) 
p-value 0.20 0.04 0.82 0.23 
The OR (95% CI) are from generalized estimating equations adjusted for maternal early pregnancy 
BMI, gestational weight gain rate, time of the first weight measurement (≤10.0 vs >10 weeks of 
pregnancy) glucose intolerance diet, education, smoking during pregnancy, and duration of 
breastfeeding. p-values are based on type 3 Score test. The fatty acid variables used in statistical 
analysis were energy-adjusted using Willett’s residual method after logarithmic transformation. The 
sum of the 18:1 isomers consists mainly of oleic acid (18:1 n-9) and cis-vaccenic acid (18:1 n-7). 
WHO = World Health Organization; E% = percent of daily energy intake; SFA = Saturated fatty 
acid; MUFA = Monounsaturated fatty acid; PUFA = Polyunsaturated fatty acid; DHA = 
Docosahexaenoic acid; EPA = Eicosapentaenoic acid. Q1 =1
st quartile; Q2-3 = the 2 middle quartiles; 
Q4 = 4
th quartile.  
 
